$VAC.OL #Vaccibody Vaccibody - Doses first patient in Phase 2 VB10.16 trial: First VB10.16 dose administered in the VB C-02 trial Encouraging Phase 1/2a results supports study rationale Targeting up to 50 patients, completion in H1’22e https://t.co/d7ny8WrPVQ #equity #stocks